FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553630250> ?p ?o ?g. }

• W2553630250 abstract "Abstract ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT), is currently being developed for the treatment of hemophilia and rare bleeding disorders. It has previously been demonstrated that once weekly dosing of ALN-AT3 results in potent, dose-dependent and reversible silencing of plasma AT in multiple preclinical species. In the mouse, steady state ED50 knockdown was achieved following weekly doses of 0.5 mg/kg. The objective of this study was to evaluate and compare the tolerability (exaggerated pharmacology) of ALN-AT3 when administered weekly to wild-type (WT) versus hemophilia A (HA) mice. Methods ALN-AT3, diluted in PBS, was administered once weekly (x 7 weeks) via subcutaneous injection at 0, 10, 30, and 100 (HA only) mg/kg. The dose levels used in this study represented 20-, 60- and 200-fold dose multiples of the mouse ED50. Five animals per group were to be terminated on Days 23 and 44 for post-mortem evaluation. Potential test article-related effects were evaluated by clinical signs, body weight, clinical pathology (hematology, coagulation), macroscopic observations at necropsy, organ weights, and histopathology of select tissues (eye, heart, kidney, liver, lung, spleen, gross lesions). The pharmacodynamic effects of ALN-AT3 were evaluated by plasma AT protein assay. Results Repeat administration of ≥ 10 mg/kg ALN-AT3 to WT mice was not tolerated, as evidenced by early mortality (8/10 animals at 10 mg/kg, 9/10 animals at 30 mg/kg), adverse clinical signs (ocular abnormalities, craniofacial swelling, lethargy), weight loss, clinical pathology alterations (decreased PLT, increased NEU), increased relative spleen weights, and microscopic findings in heart (thrombi) and eye (hemorrhage). Residual plasma AT protein in WT and HA animals was <10% relative to control (> 90% on-target AT suppression). All findings were suggestive of thrombosis and disseminated intravascular coagulation, consistent with the intended pro-coagulant effect of AT suppression. The findings in WT animals are also consistent with heterozygous AT deficiency in humans, which is almost always lethal in utero. In contrast, repeat administration of ALN-AT3 was well tolerated in HA mice, with no adverse findings up to 100 mg/kg. In addition, HA mice exhibited significant reductions in ex vivo clotting times (aPTT) to values comparable to control WT animals, consistent with the therapeutic hypothesis of rebalancing the hemostatic system in the disease condition. Collectively, the data also suggest an expanded therapeutic index of AT suppression in the hemophilia disease condition. Disclosures: Barros: Alnylam Pharmaceuticals: Employment. Carioto:Alnylam Pharmaceuticals: Employment. Hettinger:Alnylam Pharmaceuticals: Employment. Jiang:Alnylam Pharmaceuticals: Employment. Qin:Alnylam Pharmaceuticals: Employment. Prabhala:Alnylam Pharmaceuticals: Employment. Sehgal:Alnylam Pharmaceuticals: Employment. Akinc:Alnylam Pharmaceuticals: Employment." @default.
• W2553630250 created "2016-11-30" @default.
• W2553630250 creator A5000034424 @default.
• W2553630250 creator A5010655062 @default.
• W2553630250 creator A5011250594 @default.
• W2553630250 creator A5012506815 @default.
• W2553630250 creator A5021316265 @default.
• W2553630250 creator A5034410702 @default.
• W2553630250 creator A5077685566 @default.
• W2553630250 creator A5091430910 @default.
• W2553630250 date "2013-11-15" @default.
• W2553630250 modified "2023-09-27" @default.
• W2553630250 title "Expanded Therapeutic Index Of Antithrombin Silencing and Correction Of Aptt In a Hemophilia A Mouse Model" @default.
• W2553630250 doi "https://doi.org/10.1182/blood.v122.21.3585.3585" @default.
• W2553630250 hasPublicationYear "2013" @default.
• W2553630250 type Work @default.
• W2553630250 sameAs 2553630250 @default.
• W2553630250 citedByCount "0" @default.
• W2553630250 crossrefType "journal-article" @default.
• W2553630250 hasAuthorship W2553630250A5000034424 @default.
• W2553630250 hasAuthorship W2553630250A5010655062 @default.
• W2553630250 hasAuthorship W2553630250A5011250594 @default.
• W2553630250 hasAuthorship W2553630250A5012506815 @default.
• W2553630250 hasAuthorship W2553630250A5021316265 @default.
• W2553630250 hasAuthorship W2553630250A5034410702 @default.
• W2553630250 hasAuthorship W2553630250A5077685566 @default.
• W2553630250 hasAuthorship W2553630250A5091430910 @default.
• W2553630250 hasConcept C111113717 @default.
• W2553630250 hasConcept C112705442 @default.
• W2553630250 hasConcept C126322002 @default.
• W2553630250 hasConcept C142724271 @default.
• W2553630250 hasConcept C194409129 @default.
• W2553630250 hasConcept C197934379 @default.
• W2553630250 hasConcept C19831878 @default.
• W2553630250 hasConcept C2777260799 @default.
• W2553630250 hasConcept C2777288759 @default.
• W2553630250 hasConcept C2777557582 @default.
• W2553630250 hasConcept C2778375690 @default.
• W2553630250 hasConcept C2779026020 @default.
• W2553630250 hasConcept C2780035454 @default.
• W2553630250 hasConcept C2780091579 @default.
• W2553630250 hasConcept C544855455 @default.
• W2553630250 hasConcept C71924100 @default.
• W2553630250 hasConcept C90924648 @default.
• W2553630250 hasConcept C98274493 @default.
• W2553630250 hasConceptScore W2553630250C111113717 @default.
• W2553630250 hasConceptScore W2553630250C112705442 @default.
• W2553630250 hasConceptScore W2553630250C126322002 @default.
• W2553630250 hasConceptScore W2553630250C142724271 @default.
• W2553630250 hasConceptScore W2553630250C194409129 @default.
• W2553630250 hasConceptScore W2553630250C197934379 @default.
• W2553630250 hasConceptScore W2553630250C19831878 @default.
• W2553630250 hasConceptScore W2553630250C2777260799 @default.
• W2553630250 hasConceptScore W2553630250C2777288759 @default.
• W2553630250 hasConceptScore W2553630250C2777557582 @default.
• W2553630250 hasConceptScore W2553630250C2778375690 @default.
• W2553630250 hasConceptScore W2553630250C2779026020 @default.
• W2553630250 hasConceptScore W2553630250C2780035454 @default.
• W2553630250 hasConceptScore W2553630250C2780091579 @default.
• W2553630250 hasConceptScore W2553630250C544855455 @default.
• W2553630250 hasConceptScore W2553630250C71924100 @default.
• W2553630250 hasConceptScore W2553630250C90924648 @default.
• W2553630250 hasConceptScore W2553630250C98274493 @default.
• W2553630250 hasLocation W25536302501 @default.
• W2553630250 hasOpenAccess W2553630250 @default.
• W2553630250 hasPrimaryLocation W25536302501 @default.
• W2553630250 hasRelatedWork W1749517366 @default.
• W2553630250 hasRelatedWork W1903634501 @default.
• W2553630250 hasRelatedWork W1981639462 @default.
• W2553630250 hasRelatedWork W1986570095 @default.
• W2553630250 hasRelatedWork W2015897382 @default.
• W2553630250 hasRelatedWork W2039661159 @default.
• W2553630250 hasRelatedWork W2042848882 @default.
• W2553630250 hasRelatedWork W2068772014 @default.
• W2553630250 hasRelatedWork W2080936300 @default.
• W2553630250 hasRelatedWork W2096498988 @default.
• W2553630250 hasRelatedWork W2320215042 @default.
• W2553630250 hasRelatedWork W2588484939 @default.
• W2553630250 hasRelatedWork W2618040829 @default.
• W2553630250 hasRelatedWork W2625275387 @default.
• W2553630250 hasRelatedWork W2742525810 @default.
• W2553630250 hasRelatedWork W2918113078 @default.
• W2553630250 hasRelatedWork W2985909449 @default.
• W2553630250 hasRelatedWork W2995361346 @default.
• W2553630250 hasRelatedWork W3041558846 @default.
• W2553630250 hasRelatedWork W3188115218 @default.
• W2553630250 isParatext "false" @default.
• W2553630250 isRetracted "false" @default.
• W2553630250 magId "2553630250" @default.
• W2553630250 workType "article" @default.